Bibliographic record

Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis

Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V. New England Journal of Medicine 2025

Document identifier: CEI-BR-099
Series: Bibliographic record
Version: 1.0
Published: 30 Jul 2026
Last reviewed: 30 Jul 2026
Certainty: Not rated

§1Bibliographic record

§1.1Record

Authors: Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V
Title: Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
Source: New England Journal of Medicine
Year: 2025
Volume, issue, pages: 392(21):2089–2099
Digital object identifier: 10.1056/NEJMoa2413258
PubMed identifier: not held by the Institute
Record type: Journal article
Institute identifier: CEI-BR-099

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Semaglutide	Compound monograph
Trial abstract: ESSENCE	Trial abstract
Synthesis: Incretin receptor agonists for metabolic dysfunction-associated…	Evidence synthesis
3 citing documents.

§1.3Subject tags

semaglutide mash ESSENCE

Compound Evidence Institute · CEI-BR-099 · https://compoundevidence.com/bibliography/sanyal2025/ · retrieved 30 July 2026